BlueSpruce Investments LP Invests $758,000 in Agilent Technologies, Inc. $A

BlueSpruce Investments LP purchased a new stake in Agilent Technologies, Inc. (NYSE:A) in the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 6,427 shares of the medical research company’s stock, valued at approximately $758,000. Agilent Technologies makes up 0.0% of BlueSpruce Investments LP’s investment portfolio, making the stock its 22nd biggest position.

A number of other hedge funds have also recently added to or reduced their stakes in A. Ameriprise Financial Inc. lifted its position in shares of Agilent Technologies by 132.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock valued at $277,807,000 after acquiring an additional 1,340,161 shares during the period. AQR Capital Management LLC raised its stake in Agilent Technologies by 424.1% in the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after purchasing an additional 1,652,244 shares in the last quarter. California State Teachers Retirement System lifted its position in Agilent Technologies by 2.1% during the second quarter. California State Teachers Retirement System now owns 469,910 shares of the medical research company’s stock worth $55,454,000 after purchasing an additional 9,442 shares during the period. Canada Pension Plan Investment Board grew its stake in Agilent Technologies by 4.9% during the second quarter. Canada Pension Plan Investment Board now owns 78,915 shares of the medical research company’s stock worth $9,313,000 after buying an additional 3,711 shares in the last quarter. Finally, Quantinno Capital Management LP increased its holdings in Agilent Technologies by 128.0% in the 2nd quarter. Quantinno Capital Management LP now owns 150,345 shares of the medical research company’s stock valued at $17,742,000 after buying an additional 84,416 shares during the period. Institutional investors own 87.41% of the company’s stock.

Agilent Technologies Stock Performance

Shares of A stock opened at $139.56 on Friday. The firm has a market capitalization of $39.57 billion, a price-to-earnings ratio of 30.54, a PEG ratio of 4.15 and a beta of 1.27. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 0.45. The business’s 50-day moving average price is $145.59 and its 200-day moving average price is $129.02. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $160.27.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.01. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. The business had revenue of $1.86 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same quarter last year, the business earned $1.46 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. Equities research analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Investors of record on Tuesday, January 6th will be given a dividend of $0.255 per share. The ex-dividend date of this dividend is Tuesday, January 6th. This represents a $1.02 annualized dividend and a yield of 0.7%. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.25. Agilent Technologies’s dividend payout ratio is 22.32%.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 12,490 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $150.00, for a total transaction of $1,873,500.00. Following the completion of the transaction, the chief executive officer directly owned 33,448 shares in the company, valued at $5,017,200. This trade represents a 27.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Rodney Gonsalves sold 3,000 shares of Agilent Technologies stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $154.99, for a total value of $464,970.00. Following the completion of the transaction, the vice president directly owned 31,846 shares in the company, valued at approximately $4,935,811.54. This represents a 8.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 16,401 shares of company stock valued at $2,468,962. 0.26% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on A. Wells Fargo & Company increased their price target on shares of Agilent Technologies from $150.00 to $175.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 25th. The Goldman Sachs Group started coverage on Agilent Technologies in a research note on Tuesday. They issued a “buy” rating and a $170.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on Agilent Technologies from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Tuesday, November 25th. Bank of America raised their price objective on Agilent Technologies from $150.00 to $165.00 and gave the company a “neutral” rating in a research note on Tuesday, November 25th. Finally, Wall Street Zen raised Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $161.77.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.